J
J. Rifa
Publications - 5
Citations - 290
J. Rifa is an academic researcher. The author has contributed to research in topics: Lung cancer & CYFRA 21-1. The author has an hindex of 3, co-authored 5 publications receiving 266 citations.
Papers
More filters
Journal ArticleDOI
Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis: Comparison with the main clinical and pathological prognostic factors
Rafael Molina,Xavier Filella,Josep M. Augé,R. Fuentes,I. Bover,J. Rifa,Victor Moreno,E. Canals,Nuria Viñolas,A. Marquez,Esther Barreiro,Josep M. Borràs,P. Viladiu +12 more
TL;DR: All tumor markers showed a clear relationship with tumor stage and histology and therefore enabled a better histological diagnosis and helped in the diagnosis of non-small cell lung cancer.
Journal ArticleDOI
Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis
Xavier Garcia-del-Muro,C. Vadell,G. Pérez Manga,I. Bover,J. Rifa,M. Beltrán,M.a.M. Barros,J.R. Germà,X. Fabregat,Victor Moreno,A. Salvador,P. Viladiu +11 more
TL;DR: Trisetron in combination with dexamethasone is safe and more effective than tropisetron alone in the prevention of both acute and delayed cisplatin-induced emesis.
Journal ArticleDOI
Tumor markers (CEA, CA 125, CYFRA 21.1, SCC and NSE) in non small cell lung cancer (NSCLC) patients as an aid in histological diagnosis and prognosis: Comparison with the main clinical and pathological prognostic factors
Nuria Viñolas,Rafael Molina,R. Fuentes,Isabel Bover,J. Rifa,Victor Moreno,E. Canals,A. Marquez,Esther Barreiro,J. Borrás,X Filella,J Jo,X Navarro,P. Viladiu,A.M Ballesta +14 more
Journal ArticleDOI
Multicentric, observational, transversal study to describe the clinical profile of patients with metastatic breast cancer (MBC) treated with first-line bevacizumab (TRANSBREAST): Preliminary results.
M. Guirado-Risueno,G. Pérez Manga,J. Rifa,R. M. Perez Carrion,M. J. Garcia Lopez,Almudena Velasco,A. Oltra Ferrando,E. Barrajon,G. Lopez-Vivanco,M. Munoz-Mateu +9 more
TL;DR: The profile of patients treated under real conditions of use, their relationship with the regime used and the MBC subtypes by their genetic signature and tolerability of treatment, and the results from the first 108 pts who received at least one dose of bevacizumab are presented.